Major adverse cardiovascular events in a real-life COPD patient population

被引：0

作者：

Michotte, Naomi ^{[1
]}

Hanon, Shane ^{[1
]}

Verbanck, Sylvia ^{[1
]}

Vanderhelst, Eef ^{[1
]}

机构：

[1] Univ Hosp Brussels, Jette, Belgium

来源：

EUROPEAN RESPIRATORY JOURNAL | 2024年 / 64卷

关键词：

D O I：

10.1183/13993003.congress-2024.PA1760

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：2

共 50 条

[21] Ocular Adverse Events in Patients With Atopic Dermatitis Treated With Upadacitinib: A Real-Life Experience
Gelato, Federica
Mastorino, Luca
Quaglino, Pietro
Cavaliere, Giovanni
Ortoncelli, Michela
Ribero, Simone
DERMATITIS, 2023, : 445 - 447
[22] Mepolizumab-Related Adverse Events in Severe Eosinophilic Asthma: A Real-Life Study
Nazik Bahcecioglu, Sakine
TURK, Murat
ATAYIK, Emel
PACACI CETIN, Gulden
ARSLAN, Bahar
GULMEZ, Inci
YILMAZ, Insu
ASTIM ALLERJI IMMUNOLOJI, 2022, 20 (02): : 81 - 86
[23] Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience
Elbaz, Tamer
Elserafy, Magdy
Elakel, Wafaa
Mohey, Mohammad A.
Abdo, Mahmoud
Hassany, Mohamed
Mehrez, Mai
Abouelkhair, Mahmoud
Yosry, Ayman
Omar, Ashraf
Waked, Imam
Elsayed, Manal Hamdy
Mahran, Zakaria
Elshazly, Yahia
Elgarem, Noman
Gaballa, Aly
Doss, Wahid
Esmat, Gamal
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2017, 37 (08): : 348 - 353
[24] A COMPARISON OF ADVERSE EVENTS ASSOCIATED WITH LICENSED AND UNLICENSED SPACER USE WITH NON-EXTRAFINE BECLOMETASONE DIPROPIONATE TREATMENT IN A REAL-LIFE PATIENT POPULATION WITH ASTHMA IN THE UK
Ming, S. Wan Yau
Haughney, J.
Ryan, D.
Patel, S.
Ochel, M.
Thornhill, S.
Price, D.
THORAX, 2017, 72 : A193 - A193
[25] Prediabetes and the Incidence of Major Adverse Cardiovascular Events
Booth, Gillian L.
Rezai, Mohammad R.
Atzema, Clare
Austin, Peter C.
Bhatia, Sacha
Bierman, Arlene S.
Clemens, Kristin K.
Johnston, Sharon
Ko, Dennis T.
Lee, Douglas S.
Tu, Karen
Tu, Jack V.
DIABETES, 2017, 66 : A81 - A82
[26] The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study
Gonzalez-Juanatey, Jose R.
Cordero, Alberto
Castellano, Jose Ma
Masana, Luis
Dalmau, Regina
Ruiz, Emilio
Sicras-Mainar, Antonio
Fuster, Valentin
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 361 : 116 - 123
[27] A paradigm shift for cardiovascular outcome evaluation in diabetes: Major adverse cardiovascular events (MACE) to major adverse vascular events (MAVE)
Rastogi, Ashu
Sudhayakumar, Anand
Schaper, Nicolaas C.
Jude, Edward B.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2023, 17 (11)
[28] Antidepressants and the Risk of Cardiovascular Events in Elderly Affected by Cardiovascular Disease A Real-Life Investigation From Italy
Biffi, Annalisa
Rea, Federico
Scotti, Lorenza
Lucenteforte, Ersilia
Vannacci, Alfredo
Lombardi, Niccolo
Chinellato, Alessandro
Onder, Graziano
Vitale, Cristiana
Cascini, Silvia
Ingrasciotta, Ylenia
Roberto, Giuseppe
Mugelli, Alessandro
Corrao, Giovanni
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (02) : 112 - 121
[29] Lymphopenia is not associated with efficacy and risk of adverse events in a real-life MS population treated with fingo-limod and dimethyl fumarate
Bruschi, N.
Boffa, G.
Cellerino, M.
Sbragia, E.
Novi, G.
Lapucci, C.
Carpaneto, S.
Laroni, A.
Capello, E.
Uccelli, A.
Inglese, M.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 334 - 334
[30] EFFECT OF ACLIDINIUM BROMIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS AND EXACERBATIONS IN PATIENTS WITH COPD AND DIFFERENT CARDIOVASCULAR RISK FACTOR LEVELS
Chapman, Kenneth
Wise, Robert
Scirica, Benjamin
Schoenfeld, David
Bhatt, Deepak
Daoud, Sami
Zetterstrand, Sofia
Reisner, Colin
Gil, Esther Garcia
CHEST, 2018, 154 (04) : 1115A - 1117A

← 1 2 3 4 5 →